NCT03588611View on ClinicalTrials.gov

Reduce Bolus Injection of Bivalirudin

PHASE4CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

June 26, 2021

Study Completion Date

June 26, 2021

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Bivalirudin

0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;

DRUG

Bivalirudin

0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;

Trial Locations (1)

110016

General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

Han Yaling, MD

OTHER

NCT03588611 - Reduce Bolus Injection of Bivalirudin | Biotech Hunter | Biotech Hunter